Although several studies have demonstrated that CD4 and CD8 have an immunological anti-tumor effect, there have been studies reporting the clinical importance of the CD4/CD8 ratio in tumor-infiltrating lymphocytes and their prognosis as a marker of the gastrointestinal tumor showing progression [29,30]. The gene discussed is CD8A; the disease is neoplasm.